# Efficacy of Reslizumab Dose Escalation in Patients With Severe Asthma

> **NCT04710134** · PHASE4 · COMPLETED · sponsor: **McMaster University** · enrollment: 10 (actual)

## Conditions studied

- Asthma; Eosinophilic

## Interventions

- **BIOLOGICAL:** Reslizumab

## Key facts

- **NCT ID:** NCT04710134
- **Lead sponsor:** McMaster University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-02-10
- **Primary completion:** 2024-01-09
- **Final completion:** 2024-01-09
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2024-01-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04710134

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04710134, "Efficacy of Reslizumab Dose Escalation in Patients With Severe Asthma". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT04710134. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*